Novel therapeutic approaches in IBS.
Irritable bowel syndrome (IBS) remains an incompletely understood, common syndrome with significant unmet medical needs. Significant progress has been made in the development of novel therapies aimed at normalizing bowel habit alterations and abdominal discomfort, even though some of the most effective treatments are currently only available for patients under a restricted access program from the FDA. Preclinical evidence supports the potential usefulness of several compounds in development for the treatment of chronic abdominal pain. Recent new evidence for a possible role of altered microflora and altered host microbial interactions may provide new treatment targets in the future.
Bradesi
Sylvie
S
UCLA Center for Neurovisceral Sciences & Women's Health, and Departments of Medicine, David Geffen School of Medicine at UCLA, University of California-Los Angeles, CA 90024, USA.
Mayer
Emeran A
EA
D018663:Adrenergic Agents / Q000627:therapeutic use; D000818:Animals; D005765:Gastrointestinal Agents / Q000494:pharmacology; D006801:Humans; D007413:Intestinal Mucosa / Q000187:drug effects; D043183:Irritable Bowel Syndrome / Q000188:drug therapy*; D018013:Receptors, Neuropeptide / Q000187:drug effects; D018490:Serotonin Agents / Q000627:therapeutic use
D018663:Adrenergic Agents; D005765:Gastrointestinal Agents; D018013:Receptors, Neuropeptide; D018490:Serotonin Agents